UroGen Pharma Ltd. Forecast, price target & analysts
UroGen Pharma Ltd. Target price 2025 - Analyst rating & recommendation
UroGen Pharma Ltd. Classifications & Recommendation:
UroGen Pharma Ltd. Price Target
| Target Price | $32.64 |
| Price | $18.80 |
| Potential |
73.62%
register free of charge
|
| Number of Estimates | 9 |
|
9 Analysts have issued a price target UroGen Pharma Ltd. 2026 .
The average UroGen Pharma Ltd. target price is $32.64.
This is
73.62%
register free of charge
$43.05
128.99%
register free of charge
$16.16
14.04%
register free of charge
|
|
| A rating was issued by 14 analysts: 12 Analysts recommend UroGen Pharma Ltd. to buy, 2 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the UroGen Pharma Ltd. stock has an average upside potential 2026 of
73.62%
register free of charge
|
Sales and Margin forecast 2025, 2026 to 2032
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Million $ | 90.40 | 122.58 |
| 9.30% | 35.60% | |
| EBITDA Margin | -105.75% | -103.55% |
| 37.03% | 2.08% | |
| Net Margin | -140.34% | -108.69% |
| 13.53% | 22.55% |
9 Analysts have issued a sales forecast UroGen Pharma Ltd. 2025 . The average UroGen Pharma Ltd. sales estimate is
This results in the following potential growth metrics:
3 Analysts have issued an UroGen Pharma Ltd. EBITDA forecast 2025. The average UroGen Pharma Ltd. EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
9 UroGen Pharma Ltd. Analysts have issued a net profit forecast 2025. The average UroGen Pharma Ltd. net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2032
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -2.96 | -2.88 |
| 16.62% | 2.70% | |
| P/E | negative | |
| EV/Sales | 7.06 |
9 Analysts have issued a UroGen Pharma Ltd. forecast for earnings per share. The average UroGen Pharma Ltd. EPS is
This results in the following potential growth metrics and future valuations:
UroGen Pharma Ltd....
Current UroGen Pharma Ltd. Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Piper Sandler |
Locked
➜
Locked
|
Locked | Aug 19 2025 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Aug 11 2025 |
| D. Boral Capital |
Locked
➜
Locked
|
Locked | Aug 07 2025 |
| D. Boral Capital |
Locked
➜
Locked
|
Locked | Aug 05 2025 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Jul 08 2025 |
| D. Boral Capital |
Locked
➜
Locked
|
Locked | Jul 07 2025 |
| Guggenheim |
Locked
➜
Locked
|
Locked | Jun 13 2025 |
| Analyst Rating | Date |
|---|---|
|
Locked
Piper Sandler:
Locked
➜
Locked
|
Aug 19 2025 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Aug 11 2025 |
|
Locked
D. Boral Capital:
Locked
➜
Locked
|
Aug 07 2025 |
|
Locked
D. Boral Capital:
Locked
➜
Locked
|
Aug 05 2025 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Jul 08 2025 |
|
Locked
D. Boral Capital:
Locked
➜
Locked
|
Jul 07 2025 |
|
Locked
Guggenheim:
Locked
➜
Locked
|
Jun 13 2025 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
